Biotech Values

[turtlepower]

ECYT - Not sure that the company had publicly stated the percentage of FR++. The percentage who are at least FR+ is 80% of Ovarian cancer patients.

I think they adjusted for platinum use, perhaps age and geography and also time since last platinum use. One of their theories for the OS being longer in the control arm was that more patients had been placed on platinum post trial and more of those patients had been platinum free for greater than 3 months which made them more platinum sensitive.